文献速递银屑病与炎症性皮肤病

依奇珠单抗治疗中重度生殖器银屑病的随机双盲安慰剂对照IIIb期研究:疗效与安全性

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
PubMed 文献 · Br J Dermatol · 2018-07-22

这项随机双盲安慰剂对照IIIb期研究纳入中重度生殖器银屑病且受累体表面积≥1%的患者,按1:1随机接受安慰剂(n=74)或依奇珠单抗推荐剂量(n=75)。第12周时,依奇珠单抗在sPGA-G 0/1、总体sPGA 0/1、GenPs-SFQ第2项评分0/1及生殖器瘙痒方面均优于安慰剂,安全性特征与既往中重度斑块状银屑病研究一致。

要点

  • 第12周sPGA-G 0/1:依奇珠单抗组73% vs 安慰剂组8%(P<0.001)。
  • 第12周生殖器瘙痒≥3分改善:依奇珠单抗组60% vs 安慰剂组8%(P<0.001)。
  • 未报告念珠菌感染、无死亡,安慰剂组报告1例(1%)严重不良事件。

核心结论

  • 依奇珠单抗在治疗受累体表面积≥1%的中重度生殖器银屑病方面优于安慰剂,其安全性特征与既往中重度斑块状银屑病研究一致。

研究设计与样本

  • 随机、双盲、安慰剂对照IIIb期研究,中重度生殖器银屑病患者按1:1随机接受安慰剂(n=74)或依奇珠单抗推荐剂量(n=75)。

主要发现

  • 第12周sPGA-G 0/1:依奇珠单抗组73% vs 安慰剂组8%(P<0.001)。
  • 第12周总体sPGA 0/1:依奇珠单抗组73% vs 安慰剂组3%(P<0.001)。
  • 第12周GenPs-SFQ第2项评分0/1:依奇珠单抗组78% vs 安慰剂组21%(P<0.001)。
  • 第12周生殖器瘙痒数值评定量表较基线改善≥3分:依奇珠单抗组60% vs 安慰剂组8%(P<0.001)。
  • 未报告念珠菌感染、无死亡发生,安慰剂组1例(1%)报告严重不良事件。

关键数值与推荐

  • 中重度生殖器银屑病定义为基线生殖器静态医生总体评估(sPGA-G)评分≥3且受累体表面积≥1%。
  • 主要终点为第12周达到sPGA-G评分0或1的患者百分比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genital psoriasis (GenPs) is a common, debilitating and difficult-to-treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist. OBJECTIVES: To determine the efficacy of ixekizumab vs. placebo in patients with moderate-to-severe GenPs with ≥ 1% involved body surface area (BSA). METHODS: Patients with moderate-to-severe GenPs, defined as a baseline static Physician's Global Assessment of Genitalia (sPGA-G) score of ≥ 3, with BSA ≥ 1% were randomized 1 : 1 to receive placebo (n = 74) or the recommended dosing of ixekizumab (n = 75). Major outcomes included the percentage of patients achieving 0 or 1 scores on the sPGA-G (primary end point), overall sPGA, GenPs Sexual Frequency Questionnaire (GenPs-SFQ) item 2, and ≥ 3-point improvement from baseline on the GenPs itch numerical rating scale. RESULTS: At week 12, ixekizumab was superior to placebo for sPGA-G 0/1 (73% vs. 8%, P < 0·001), overall sPGA 0/1 (73% vs. 3%, P < 0·001), GenPs-SFQ item 2 score of 0 or 1 (78% vs. 21%, P < 0·001) and genital itch (60% vs. 8%, P < 0·001). No candidiasis was reported, no deaths occurred and one (1%) serious adverse event was reported in a patient receiving placebo. CONCLUSIONS: Ixekizumab was superior to placebo for the treatment of moderate-to-severe GenPs with BSA ≥ 1%. The safety profile of ixekizumab was consistent with previous studies in moderate-to-severe plaque psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018. PMID: 29747232. doi:10.1111/bjd.16736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。